Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose?: Findings from the SHIFT (Systolic Heart failure treatment with the I f inhibitor ivabradine Trial) study

Journal of the American College of Cardiology

Volumn 59, Issue 22, 2012, Pages 1938-1945

  Swedberg, Karl ^a   Komajda, Michel ^b   Böhm, Michael ^c   Borer, Jeffrey ^d   Robertson, Michele ^e   Tavazzi, Luigi ^f   Ford, Ian ^e  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SORBONNE UNIVERSITÉ   (France)

^c SAARLAND UNIVERSITY   (Germany)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f Research Ettore Sansavini Health Science Foundation   (Italy)

Author keywords

beta blockade; chronic heart failure; heart rate; ivabradine; treatment

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; IVABRADINE; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; SYSTOLIC HEART FAILURE; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; BENZAZEPINES; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, SYSTOLIC; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SINOATRIAL NODE; SURVIVAL RATE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; WORLD HEALTH;

EID: 84861527957     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.01.020     Document Type: Article

References (22)

1. P.S. Jhund, K. Macintyre, C.R. Simpson Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people Circulation 119 2009 515 523
2. M. Schaufelberger, K. Swedberg, M. Köster, M. Rosén, A. Rosengren Decreasing one-year mortality and hospitalization rates for heart failure in Sweden: data from the Swedish Hospital Discharge Registry 1988 to 2000 Eur Heart J 25 2004 300 307
3. K. Dickstein, A. Cohen-Solal, G. Filippatos ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology Eur J Heart Fail 10 2008 933 989
4. F.A. McAlister, N. Wiebe, J.A. Ezekowitz, A.A. Leung, P.W. Armstrong Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure Ann Intern Med 150 2009 784 794
5. L. Wilhelmsen, G. Berglund, D. Elmfeldt The multifactor primary prevention trial in Göteborg, Sweden Eur Heart J 7 1986 279 288
6. A. Diaz, M.G. Bourassa, M.C. Guertin, J.C. Tardif Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease Eur Heart J 26 2005 967 974
7. M. Bohm, K. Swedberg, M. Komajda Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial Lancet 376 2010 886 894
8. K. Swedberg, M. Komajda, M. Bohm Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 376 2010 875 885
9. K. Swedberg, M. Komajda, M. Bohm, J.S. Borer, I. Ford, L. Tavazzi Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial (SHIFT) Eur J Heart Fail 12 2010 75 81
10. K. Swedberg, J. Cleland, H. Dargie Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur Heart J 26 2005 1115 1140
11. J.K. McGavin, G.M. Keating Bisoprolol: a review of its use in chronic heart failure Drugs 62 2002 2677 2696
12. D. McTavish, D. Campoli Richards, E.M. Sorkin Carvedilol A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy Drugs 45 1993 232 258
13. The CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
14. The MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
15. M. Packer, A.J. Coats, M.B. Fowler Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
16. T. Simon, M. Mary-Krause, C. Funck-Brentano, P. Lechat, P. Jaillon Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II) Eur Heart J 24 2003 552 559
17. M. Metra, C. Torp-Pedersen, K. Swedberg Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial Eur Heart J 26 2005 2259 2268
18. D. Dobre, C.H. van Jaarsveld, M.J. deJongste, F.M. Haaijer Ruskamp, A.V. Ranchor The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis Pharmacoepidemiol Drug Saf 16 2007 152 159
19. H.D. Dungen, S. Apostolovic, S. Inkrot Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial Eur J Heart Fail 13 2011 670 680
20. A.P. Maggioni, U. Dahlstrom, G. Filippatos EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot) Eur J Heart Fail 12 2010 1076 1084
21. H. Persson, H. Erntell, B. Eriksson, G. Johansson, K. Swedberg, U. Dahlstrom Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure - SIGNAL-HF (Swedish Intervention study - Guidelines and NT-proBNP AnaLysis in Heart Failure) Eur J Heart Fail 12 2010 1300 1308
22. R. Lowrie, F.S. Mair, N. Greenlaw The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics Eur J Heart Fail 13 2011 917 924